Skip to main content
SpringerLink
Log in

Expression of leukemia inhibitory factor and its receptor in breast cancer: A potential autocrine and paracrine growth regulatory mechanism

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Leukemia inhibitory factor (LIF) is a pluripotent cytokine which has a diverse array of effects on hematopoietic and epithelial cells. Depending on the nature of the target cells, these effects can be growth-stimulatory or growth-inhibitory. Receptors for leukemia inhibitory factor (LIFR) have been identified on a variety of hematopoietic and epithelial cells. We have recently demonstrated in vitro growth stimulation of human breast cancer cells, both primary tumors and cultured cell lines, by LIF. To begin to understand the in vivo relevance of these observations, we investigated the expression of LIF and LIFR in human breast cancer specimens. Specimens from 50 cases were immunostained with mouse monoclonal antibodies D62.3 and M1 (to stain for LIF and LIFR, respectively). LIF expression was observed in 78% of the specimens and correlated with favorable biological features, i.e. low S-phase fraction (SPF) (P=0.001) and diploidy (P = 0.08). LIFR expression was observed in 80% of the tumors and correlated with the presence of estrogen receptor (ER) (P=0.04) and diploidy (P=0.07). Coexpression of LIF and LIFR was associated with diploidy (P=0.02) and low SPF (P=0.05). LIF staining was primarily cytoplasmic whereas LIFR staining was cytoplasmic in the majority of cases and membranous in a minority of cases. The presence of LIFR in the primary tumor specimens correlated with the growth stimulation of tumor cells (derived from the same specimens) by exogenous LIF in methylcellulose colony assays. The findings support a widespread but probably complex role for LIF and LIFR in breast tumor growth regulation which should be investigated in greater detail in larger cohorts of tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tomida M, Yamamoto-Yamaguchi Y, Hozumi M: Purification of a factor inducing differentiation of mouse myeloid leukemic M1cells from conditioned medium of mouse fibroblast L929 cells. J Biol Chem 259: 10978-10982, 1984

    Google Scholar 

  2. Vlasselaer PV: Leukemia inhibitory factor (LIF): a growth factor with pleiotropic effects on bone biology. Prog Growth Factor Res 4: 337-353, 1992

    Google Scholar 

  3. Metcalf D: Leukemia inhibitory factor - a puzzling poly-functional regulator. Growth Factors 7: 169-173, 1992

    Google Scholar 

  4. Cheng L, Gearing DP, White LS, Compton DL, Schooley K, Donovan PJ: Role of leukemia inhibitory factor and its receptor in mouse primordial germ cell growth. Development 120: 3145-3153, 1994

    Google Scholar 

  5. Smith AG, Heath JK, Donaldson DD, Wong GG, Moreau J, Stahl M, Rogers D: Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. Nature 336: 688-690, 1988

    Google Scholar 

  6. Matsui Y, Toksoz D, Nishikawa S, Nishikawa S, Williams D, Zsebo K, Hogan BLM: Effect of Steelfactor and leukemia inhibitory factor on murine primordial germ cells in culture. Nature 353: 750-752, 1991

    Google Scholar 

  7. Arici A, Engin O, Attar E, Olive DL: Modulation of leukemia inhibitory factor gene expression and protein biosynthesis in human endometrium. J Clin Endocrinol Metab 80: 1908-1915, 1995

    Google Scholar 

  8. Wetzler M, Talpaz M, Lowe DG, Baiocchi G, Gutterman JU, Kurzrock R: Constitutive expression of leukemia inhibitory factor RNA by human bone marrow stromal cells and modulation by IL-1, TNF-?, and TNF-?. Exp Hematol 19: 347-351, 1991

    Google Scholar 

  9. Wetzler M, Estrov Z, Talpaz M, Kim KJ, Alphonso M, Srinivasan R, Kurzrock R: Leukemia inhibitory factor in longterm adherent layer cultures: increased levels of bioactive protein in leukemia and modulation by IL-4, IL-1?, and TNF-?. Cancer Res 54: 1837-1842, 1994

    Google Scholar 

  10. Mattei S, Colombo MP, Melani C, Silvani A, Parmiani G, Herlyn M: Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 56: 853-857, 1994

    Google Scholar 

  11. Kamohara H, Sakamota K, Ishiko T, Mita S, Masuda Y, Abe T, Ogawa M: Human carcinoma cell lines produce biologically active leukemia inhibitory factor (LIF). Res Comm Mol Path Pharmacol 85: 131-140, 1994

    Google Scholar 

  12. Paglia D, Oran A, Lu C, Kerbel RS, Sauder DN, McKenzie RC: Expression of leukemia inhibitory factor and interleukin-11 by human melanoma cell lines: LIF, IL-6, and IL-11 are not coregulated. J Interferon Cytokine Res 15: 455-460, 1995

    Google Scholar 

  13. Thoma B, Bird TA, Friend DJ, Gearing DP, Dower SK: Oncostatin M and leukemia inhibitory factor trigger overlapping and different signals through partially shared receptor complexes. J Biol Chem 269: 6215-6222, 1994

    Google Scholar 

  14. Yin T, Yang Y: Mitogen-activated protein kinases and ribosomal S6 protein kinases are involved in signaling pathways shared by interleukin-11, interleukin-6, leukemia inhibitory factor, and oncostatin M in mouse 3T3-L1 cells. J Biol Chem 269: 3731-3738, 1994

    Google Scholar 

  15. Stahl N, Boulton TG, Farruggella T, Ip NY, Davis S, Witthuhn BA, Quelle FW, Silvennoinen O, Barbieri G, Pellegrini S, Ihle JN, Yancopoulos GD: Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 ??receptor components. Science 263: 92-95, 1994

    Google Scholar 

  16. Davis S, Aldrich TH, Stahl N, Pan L, Taga T, Kishimoto T, Ip NY, Yancopoulos GD: LIFR ??and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science 260: 1805-1808, 1993

    Google Scholar 

  17. Boulton TG, Stahl N, Yancopoulos GD: Ciliary neurotrophic factor/leukemia inhibitory factor/interleukin 6/oncostatin M family of cytokines induces tyrosine phosphorylation of a common set of proteins overlapping those induced by other cytokines and growth factors. J Biol Chem 269: 11648-11655, 1994

    Google Scholar 

  18. Modrell B, Liu J, Miller H, Shoyab M: LIF and OM directly interact with a soluble form of gp130, the IL-6 receptor signal transducing subunit. Growth Factors 11: 81-91, 1994

    Google Scholar 

  19. Gearing DP, Ziegler SF, Comeau MR, Friend D, Thoma B, Cosman D, Park L, Mosley B: Proliferative responses and binding properties of hematopoietic cells transfected with low-affinity receptor for leukemia inhibitory factor, onco174 statin M, and ciliary neurotrophic factor. Proc Natl Acad Sci USA 91: 1119-1123, 1994

    Google Scholar 

  20. Hilton DJ, Nicola NA, Metcalf D: Specific binding of murine leukemia inhibitory factor to normal and leukemic monocytic cells. Proc Natl Acad Sci USA 85: 5971-5975, 1988

    Google Scholar 

  21. Godard A, Heymann D, Raher S, Anegon I, Peyrat M, le Mauff B, Mouray E, Gregoire M, Virdee K, Soulillou J, Moreau J, Jacques Y: High and low affinity receptors for human interleukin for DA cells/leukemia inhibitory factor on human cells-molecular characterization and cellular distribution. J Biol Chem 267: 3214-3222, 1992

    Google Scholar 

  22. Mansi JL, Berger U, McDonnell T, Pople A, Rayter Z, Gazet JC, Coombes RC: The fate of bone marrow micrometastases in patients with primary breast cancer. J Clin Oncol 7: 445-449, 1989

    Google Scholar 

  23. Estrov Z, Samal B, Lapushin R, Kellokumpu-Lehtinen P, Sahin AA, Kurzrock R, Talpaz M, Aggarwal BB: Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation. J Interferon Cytokine Res 15: 905-913, 1995

    Google Scholar 

  24. Black MM: Nuclear structure in cancer tissues. Surg Gynecol Obstet 105: 97-102, 1957

    Google Scholar 

  25. Kim KJ, Alphonso M, Schmelzer CH, Lowe D: Detection of human leukemia inhibitory factor by monoclonal antibody based ELISA. J Immunol Methods 156: 9-17, 1992

    Google Scholar 

  26. Cho S-H, Sahin A, Hortobagyi GN, Hittelman WN, Dhingra K: Sialyl-Tn antigen expression occurs early during human mammary carcinogenesis and is associated with high nuclear grade and aneuploidy. Cancer Res 54: 6302-6305, 1994

    Google Scholar 

  27. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200-206, 1993

    Google Scholar 

  28. Andersen J, Thorpe SM, King WJ, Rose C, Christensen I, Rasmussen BB, Poulsen HS: The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroidbinding assays. Eur J Cancer 26: 442-449, 1990

    Google Scholar 

  29. Bianchi S, Paglierani M, Zampi G, Cardona G, Cataliotti L, Bonardi R, Zappa M, Ciatto S: Prognostic value of proliferating cell nuclear antigen in lymph node-negative breast cancer patients. Cancer 72: 120-125, 1993

    Google Scholar 

  30. Altman DG, Lausen B, Sauerbrei W, Schumacher M: Dangers of using open ‘optimal’ cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86: 829-835, 1994

    Google Scholar 

  31. Jensen RA, Thompson ME, Jetton TL, Szabo CI, van der Meer R, Helou B, Tronick SR, Page DL, King M-C, Holt JT: BRCA 1 is secreted and exhibits properties of a granin. Nature Genet 12: 303-308, 1996

    Google Scholar 

  32. Dutrillaux B, Gerbault-Seureau M, Remvikos Y, Zafrani B, Prieur M: Breast cancer genetic evolution: I. Data from cytogenetics and DNA content. Breast Cancer Res Treat 19: 245-255, 1991

    Google Scholar 

  33. Remvikos Y, Gerbault-Seureau M, Magdelénat H, Prieur M, Dutrillaux B: Proliferative activity of breast cancers increases in the course of genetic evolution as defined by cytogenetic analysis. Breast Cancer Res Treat 23: 43-49, 1992

    Google Scholar 

  34. Killeen JL, Namiki H: DNA analysis of ductal carcinoma in situof the breast: A comparison with histologic features. Cancer 68: 2602-2607, 1991

    Google Scholar 

  35. Lowe C, Cornish J, Callon K, Martin TJ, Reid IR: Regulation of osteoblast proliferation by leukemia inhibitory factor. J Bone Miner Res 6: 1277, 1991

    Google Scholar 

  36. Noda M, Vogel RL, Hasson DM, Rodan GA: Leukemia inhibitory factor suppresses proliferation, alkaline phosphatase activity, and type I collagen messenger ribonucleic acid level and enhances osteopontin mRNA level in murine osteoblast-like (MC3T3E1) cells. Endocrinology 127: 185-190, 1990

    Google Scholar 

  37. van Beek E, van der Wee-Pals L, van de Ruit M, Nijweide P, Papapoulos S, Lowik C: Leukemia inhibitory factor inhibits osteoclastic resorption, growth, mineralization and alkaline phosphatase activity in mouse metacarpal bones. J Bone Miner Res 8: 191-198, 1993

    Google Scholar 

  38. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA: Immunohistochemical staining for transforming growth factor ?1 associates with disease progression in human breast cancer. Cancer Res 52: 6949-6952, 1992

    Google Scholar 

  39. Kellokumpu-Lehtinen P, Talpaz M, Harris D, Van Q, Kurzrock R, Estrov Z: Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. Int J Cancer 66: 515-519, 1996

    Google Scholar 

  40. Douglas AM, Goss GA, Sutherland RL, Hilton DJ, Berndt MC, Nicola NA, Begley CG: Expression and function of members of the cytokine receptor superfamily on breast cancer cells. Oncogene 14: 661-669, 1997

    Google Scholar 

Download references

Author information

Author notes

  1. Kapil Dhingra

    Present address: Eli Lilly and Company, Indianapolis, IN, USA

Authors and Affiliations

  1. Department of Breast Medical Oncology, USA

    Kapil Dhingra, Kamal Emami & Gabriel N. Hortobagyi

  2. Division of Pathology, USA

    Aysegul Sahin

  3. Department of Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA

    Zeev Estrov

Authors
  1. Kapil Dhingra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aysegul Sahin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kamal Emami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gabriel N. Hortobagyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zeev Estrov
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dhingra, K., Sahin, A., Emami, K. et al. Expression of leukemia inhibitory factor and its receptor in breast cancer: A potential autocrine and paracrine growth regulatory mechanism. Breast Cancer Res Treat 48, 165–174 (1998). https://doi.org/10.1023/A:1005942923757

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005942923757

Search

Navigation